Founded in 1997 and listed on Euronext Paris in 2005, BioAlliance Pharma conceives and develops innovative products for the treatment of cancer, with a focus on orphan or rare diseases.
The Company develops breakthrough technologies, whether in terms of nanoparticulate formulation, mucosal delivery or targeted therapies that makes it possible to act precisely on a therapeutic target and to reduce drug resistance and/or intolerance.
BioAlliance Pharma has built a unique expertise in developing and registering drugs in Europe and in the USA. Its key expertises in Preclinical & Cli¬nical development, Regulatory Affairs, as well as Strategy & Medical Affairs, Business Development, Quality, Industrial Development and Industrial Property, are major assets for BioAlliance Pharma which aims to become a leading player in the Orphan Oncology field by coupling innovation to patient needs, leaning on an advanced product pipeline.
The Company’s growth strategy is primarily driven by the development of its orphan oncology products which meet an established and unaddressed therapeutic need for a relatively limited population of patients with very high sales potential – benefiting from more favorable price and reimbursement policies.
Two strategic programs are already at an advanced stage of their development:
- Validive® - A mucoadhesive anti-inflammatory tablet to prevent severe oral mucositis in head & neck cancer patients (International Phase II trial ongoing, results expected in 4Q14)
- Livatag® - A nanoformulated doxorubicine, innovative therapy targeting survival in HCC (International Phase III trial ongoing: 100+ patients already enrolled out of 400)
In the medium to long term, the Company could market directly these high value-added products with a strong profitability profile in order to benefit from the full profit margin generated.
Furthermore, BioAlliance Pharma has successfully developed and registered two initial drugs in Europe and the United States, demonstrating its teams’ expertise and know-how.
These products are based on BioAlliance Pharma’s innovative proprietary technology Lauriad® that makes it possible to improve the efficacy and tolerance profile of an active ingredient for the chosen indication: Loramyc®/Oravig® , indicated for the treatment of oropharyngeal candidiasis, and Sitavig®, indicated for the treatment of recurrent herpes labialis. With a strong market potential, these products are dedicated to be marketed by international partners, mainly via licensing agreements, contributing towards the funding of development projects.
BioAlliance Pharma has a successful experience in licensing deals with pharmaceutical companies around the world: Oravig®/Loramyc® is already licensed in Europe, Japan, China, South Korea, Malaysia, Taiwan and Singapore; Sitavig® is already licensed in the US, in South Korea and Israel.
BioAlliance Pharma is highly interested in collaborative opportunities to develop relationships with partners for:
- Co-development opportunities for its late-stage orphan onco products
- Licensing-out opportunities for its registered/marketed products
- In-licensing projects synergistic with its portfolio (orphan/onco) at advanced stage of development (Phase II/III).